Eligibility for intravenous thrombolysis in suspected acute myocardial infarction.

Based on the registration of all the 7,157 patients admitted during a 21-month period to the emergency ward of a single hospital in an urban area with chest pain or other symptoms suggestive of acute myocardial infarction, we studied eligibility for intravenous thrombolysis in suspected acute myocardial infarction. We have limited the present analysis to those 1,715 patients with a strong suspicion of myocardial infarction, and for these patients, we have calculated the percentages eligible for thrombolysis when various electrocardiographic and delay time criteria are applied, but we have not considered contraindications to thrombolysis. We have also calculated the proportions of all infarctions in this group that would thereby receive the treatment, and the proportions of patients treated that would develop a confirmed infarction. Using the criteria ST elevation on the initial electrocardiogram and arrival in hospital within 6 hours from onset of symptoms, 18% of patients would have been given early intravenous thrombolysis, 37% of confirmed infarctions would have been treated, and 91% of all treated patients would have developed a confirmed infarction; with a delay time criterion of 12 hours, these percentages would have been 20%, 41%, and 91%, respectively; with a criterion of 24 hours, they would have been 22%, 45%, and 90%, respectively. By not considering the initial electrocardiogram and applying only the criterion of delay time, these percentages would have been 70%, 72%, and 45%, respectively, for a delay time of 6 hours; 83%, 84%, and 45%, respectively, for a delay time of 12 hours; and 91%, 92%, and 44%, respectively, for a delay time of 24 hours.(ABSTRACT TRUNCATED AT 250 WORDS)

[1]  R. Peto,et al.  Wider inclusion criteria needed for thrombolytic therapy. , 1989, Annals of internal medicine.

[2]  J. Herlitz,et al.  Delay time in suspected acute myocardial infarction and the importance of its modification , 1989, Clinical cardiology.

[3]  L. Ekström,et al.  Effect of a media campaign on delay times and ambulance use in suspected acute myocardial infarction. , 1989, The American journal of cardiology.

[4]  L. Goldman,et al.  Candidates for thrombolysis among emergency room patients with acute chest pain. Potential true- and false-positive rates. , 1989, Annals of internal medicine.

[5]  F. Van de Werf,et al.  Intravenous tissue plasminogen activator and size of infarct, left ventricular function, and survival in acute myocardial infarction. , 1988, BMJ.

[6]  A. M. Skene,et al.  TRIAL OF TISSUE PLASMINOGEN ACTIVATOR FOR MORTALITY REDUCTION IN ACUTE MYOCARDIAL INFARCTION Anglo-Scandinavian Study of Early Thrombolysis (ASSET) , 1988, The Lancet.

[7]  L. Bolognese,et al.  RANDOMISED TRIAL OF INTRAVENOUS STREPTOKINASE, ORAL ASPIRIN, BOTH, OR NEITHER AMONG 17 187 CASES OF SUSPECTED ACUTE MYOCARDIAL INFARCTION: ISIS-2 , 1988, The Lancet.

[8]  M. O'Rourke,et al.  Limitation of myocardial infarction by early infusion of recombinant tissue-type plasminogen activator. , 1988, Circulation.

[9]  M. Cerqueira,et al.  Ventricular function and infarct size: the Western Washington Intravenous Streptokinase in Myocardial Infarction Trial. , 1988, Journal of the American College of Cardiology.

[10]  F. Sheehan,et al.  The Western Washington Intravenous Streptokinase in Acute Myocardial Infarction Randomized Trial. , 1988, Circulation.

[11]  National Heart Foundation Of Australia Coronary Thrombolysi Group CORONARY THROMBOLYSIS AND MYOCARDIAL SALVAGE BY TISSUE PLASMINOGEN ACTIVATOR GIVEN UP TO 4 HOURS AFTER ONSET OF MYOCARDIAL INFARCTION , 1988, The Lancet.

[12]  H. White,et al.  Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction. , 1987, The New England journal of medicine.

[13]  J. Herlitz,et al.  Five-year mortality rate in relation to enzyme-estimated infarct size in acute myocardial infarction. , 1987, American heart journal.

[14]  R. Balcon,et al.  What proportion of patients with myocardial infarction are suitable for thrombolysis? , 1987, British heart journal.

[15]  W. Littler,et al.  ELIGIBILITY FOR THROMBOLYTIC THERAPY IN ACUTE MYOCARDIAL INFARCTION , 1987, The Lancet.

[16]  P. Shah,et al.  Mortality and morbidity rates of patients older and younger than 75 years with acute myocardial infarction treated with intravenous streptokinase. , 1987, The American journal of cardiology.

[17]  P. Serruys,et al.  Early thrombolysis in acute myocardial infarction: limitation of infarct size and improved survival. , 1986, Journal of the American College of Cardiology.

[18]  A prospective trial of intravenous streptokinase in acute myocardial infarction (I.S.A.M.). Mortality, morbidity, and infarct size at 21 days. , 1986, The New England journal of medicine.

[19]  Use of the initial electrocardiogram to predict in-hospital complications of acute myocardial infarction. , 1986, The New England journal of medicine.

[20]  H. S. Mueller,et al.  The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. , 1985, The New England journal of medicine.

[21]  M S Golden,et al.  Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. , 1980, The New England journal of medicine.

[22]  B. Sobel,et al.  Estimation of Infarct Size in Man and its Relation to Prognosis , 1972, Circulation.